Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(1):54–59. doi: 10.1038/bjc.1997.336

Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinoma: a study of the monoclonal antibodies MIB-1 and DO-7 in formalin-fixed paraffin-embedded tumour material.

S Linder 1, C Parrado 1, U G Falkmer 1, M Blåsjö 1, P Sundelin 1, A von Rosen 1
PMCID: PMC2223797  PMID: 9218733

Abstract

Formalin-fixed paraffin-embedded material from 57 patients in whom curative resection of pancreatic carcinoma had been attempted was analysed by an immunohistochemical procedure to estimate proliferation and p53 protein expression. Using the monoclonal antibody (MAb) MIB-1, which recognizes a Ki-67 epitope, the proliferating cell index (PCI, percentage of immunoreactive tumour nuclei) and proliferating cell area (PCA, percentage of immunoreactive tumour nuclear area) were calculated using an interactive image analysis system and were compared with semiquantitative scoring of stainability. MAb DO-7, which recognizes both wild- and mutant-type p53 protein, was used to assess p53 expression in the same material. MIB-1 stainings were of high quality in 53 tumours. The median PCI was 29.7% (range 0.5-82.1%) and the median PCA was 10.6% (range 0.0-36.5%). There was a close correlation between PCI and PCA (P < 0.0001). PCI and PCA values were in conformity with the semiquantitative scoring (P < 0.0001). The p53 immunohistochemical stainings were successful in 48 tumours and the protein was expressed in 22 (46%). High PCI values (> 45%, n = 14) correlated with shorter survival time (P < 0.01). PCA (P < 0.05) and the expression of p53 protein (P < 0.001) were independent prognostic variables.

Full text

PDF
54

Images in this article

56Figure 1
on p.56
56Figure 2
on p.56

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baas I. O., van den Berg F. M., Mulder J. W., Clement M. J., Slebos R. J., Hamilton S. R., Offerhaus G. J. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol. 1996 Mar;178(3):264–267. doi: 10.1002/(SICI)1096-9896(199603)178:3<264::AID-PATH485>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  2. Barton C. M., Staddon S. L., Hughes C. M., Hall P. A., O'Sullivan C., Klöppel G., Theis B., Russell R. C., Neoptolemos J., Williamson R. C. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer. 1991 Dec;64(6):1076–1082. doi: 10.1038/bjc.1991.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berrozpe G., Schaeffer J., Peinado M. A., Real F. X., Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer. 1994 Jul 15;58(2):185–191. doi: 10.1002/ijc.2910580207. [DOI] [PubMed] [Google Scholar]
  4. Bodner S. M., Minna J. D., Jensen S. M., D'Amico D., Carbone D., Mitsudomi T., Fedorko J., Buchhagen D. L., Nau M. M., Gazdar A. F. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene. 1992 Apr;7(4):743–749. [PubMed] [Google Scholar]
  5. DiGiuseppe J. A., Hruban R. H., Goodman S. N., Polak M., van den Berg F. M., Allison D. C., Cameron J. L., Offerhaus G. J. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol. 1994 Jun;101(6):684–688. doi: 10.1093/ajcp/101.6.684. [DOI] [PubMed] [Google Scholar]
  6. Hamelin R., Laurent-Puig P., Olschwang S., Jego N., Asselain B., Remvikos Y., Girodet J., Salmon R. J., Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 1994 Jan;106(1):42–48. doi: 10.1016/s0016-5085(94)94217-x. [DOI] [PubMed] [Google Scholar]
  7. Isola J., Visakorpi T., Holli K., Kallioniemi O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 1992 Jul 15;84(14):1109–1114. doi: 10.1093/jnci/84.14.1109. [DOI] [PubMed] [Google Scholar]
  8. Kalthoff H., Schmiegel W., Roeder C., Kasche D., Schmidt A., Lauer G., Thiele H. G., Honold G., Pantel K., Riethmüller G. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene. 1993 Feb;8(2):289–298. [PubMed] [Google Scholar]
  9. Linder S., Lindholm J., Falkmer U., Blåsjö M., Sundelin P., von Rosen A. Combined use of nuclear morphometry and DNA ploidy as prognostic indicators in nonresectable adenocarcinoma of the pancreas. Int J Pancreatol. 1995 Dec;18(3):241–248. doi: 10.1007/BF02784948. [DOI] [PubMed] [Google Scholar]
  10. Lundin J., Nordling S., von Boguslawsky K., Roberts P. J., Haglund C. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res. 1995 Nov-Dec;15(6B):2659–2668. [PubMed] [Google Scholar]
  11. Lundin J., Nordling S., von Boguslawsky K., Roberts P. J., Haglund C. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology. 1996 Mar-Apr;53(2):104–111. doi: 10.1159/000227545. [DOI] [PubMed] [Google Scholar]
  12. Martin H. M., Filipe M. I., Morris R. W., Lane D. P., Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer. 1992 Apr 1;50(6):859–862. doi: 10.1002/ijc.2910500604. [DOI] [PubMed] [Google Scholar]
  13. McCormick D., Chong H., Hobbs C., Datta C., Hall P. A. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology. 1993 Apr;22(4):355–360. doi: 10.1111/j.1365-2559.1993.tb00135.x. [DOI] [PubMed] [Google Scholar]
  14. Mørkve O., Halvorsen O. J., Stangeland L., Gulsvik A., Laerum O. D. Quantitation of biological tumor markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer. Int J Cancer. 1992 Dec 2;52(6):851–855. doi: 10.1002/ijc.2910520603. [DOI] [PubMed] [Google Scholar]
  15. Parrado C., Falkmer U. G., Hög A., Falkmer S., Ahrens O., Rius F., Grimelius L. A technique for automatic/interactive assessment of the proliferating fraction of neoplastic cells in solid tumors. A methodological study on the Ki-67 immunoreactive cells in human mammary carcinomas, including a comparison with the results of conventional S-phase fraction assessments by means of DNA cytometry. Gen Diagn Pathol. 1996 Mar;141(3-4):215–227. [PubMed] [Google Scholar]
  16. Pellegata N. S., Sessa F., Renault B., Bonato M., Leone B. E., Solcia E., Ranzani G. N. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994 Mar 15;54(6):1556–1560. [PubMed] [Google Scholar]
  17. Pinder S. E., Wencyk P., Sibbering D. M., Bell J. A., Elston C. W., Nicholson R., Robertson J. F., Blamey R. W., Ellis I. O. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995 Jan;71(1):146–149. doi: 10.1038/bjc.1995.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Railo M., Nordling S., von Boguslawsky K., Leivonen M., Kyllönen L., von Smitten K. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer. 1993 Sep;68(3):579–583. doi: 10.1038/bjc.1993.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ruggeri B., Zhang S. Y., Caamano J., DiRado M., Flynn S. D., Klein-Szanto A. J. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene. 1992 Aug;7(8):1503–1511. [PubMed] [Google Scholar]
  20. Scarpa A., Capelli P., Mukai K., Zamboni G., Oda T., Iacono C., Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol. 1993 May;142(5):1534–1543. [PMC free article] [PubMed] [Google Scholar]
  21. Thompson S. J., Mellon K., Charlton R. G., Marsh C., Robinson M., Neal D. E. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol. 1992 Jun;69(6):609–613. doi: 10.1111/j.1464-410x.1992.tb15632.x. [DOI] [PubMed] [Google Scholar]
  22. Weidner N., Moore D. H., 2nd, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol. 1994 Apr;25(4):337–342. doi: 10.1016/0046-8177(94)90140-6. [DOI] [PubMed] [Google Scholar]
  23. van den Berg F. M., Baas I. O., Polak M. M., Offerhaus G. J. Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol. 1993 Feb;142(2):381–385. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES